99 related articles for article (PubMed ID: 19845431)
1. In vitro model for the prediction of clinical CYP3A4 induction using HepaRG cells.
Kaneko A; Kato M; Sekiguchi N; Mitsui T; Takeda K; Aso Y
Xenobiotica; 2009 Nov; 39(11):803-10. PubMed ID: 19845431
[TBL] [Abstract][Full Text] [Related]
2. Prediction of clinical CYP3A4 induction using cryopreserved human hepatocytes.
Kaneko A; Kato M; Endo C; Nakano K; Ishigai M; Takeda K
Xenobiotica; 2010 Dec; 40(12):791-9. PubMed ID: 20863202
[TBL] [Abstract][Full Text] [Related]
3. Simple Evaluation Method for CYP3A4 Induction from Human Hepatocytes: The Relative Factor Approach with an Induction Detection Limit Concentration Based on the
Kuramoto S; Kato M; Shindoh H; Kaneko A; Ishigai M; Miyauchi S
Drug Metab Dispos; 2017 Nov; 45(11):1139-1145. PubMed ID: 28821485
[TBL] [Abstract][Full Text] [Related]
4. A 96-well plate assay for CYP4503A induction using cryopreserved human hepatocytes.
Kamiguchi N; Aoyama E; Okuda T; Moriwaki T
Drug Metab Dispos; 2010 Nov; 38(11):1912-6. PubMed ID: 20699409
[TBL] [Abstract][Full Text] [Related]
5. The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes.
Kato M; Chiba K; Horikawa M; Sugiyama Y
Drug Metab Pharmacokinet; 2005 Aug; 20(4):236-43. PubMed ID: 16141603
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Normalization Methods To Predict CYP3A4 Induction in Six Fully Characterized Cryopreserved Human Hepatocyte Preparations and HepaRG Cells.
Vermet H; Raoust N; Ngo R; Esserméant L; Klieber S; Fabre G; Boulenc X
Drug Metab Dispos; 2016 Jan; 44(1):50-60. PubMed ID: 26467767
[TBL] [Abstract][Full Text] [Related]
7. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.
Ripp SL; Mills JB; Fahmi OA; Trevena KA; Liras JL; Maurer TS; de Morais SM
Drug Metab Dispos; 2006 Oct; 34(10):1742-8. PubMed ID: 16837568
[TBL] [Abstract][Full Text] [Related]
8. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction.
Shou M; Hayashi M; Pan Y; Xu Y; Morrissey K; Xu L; Skiles GL
Drug Metab Dispos; 2008 Nov; 36(11):2355-70. PubMed ID: 18669588
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 1A2 Messenger RNA is a More Reliable Marker than Cytochrome P450 1A2 Activity, Phenacetin O-Deethylation, for Assessment of Induction Potential of Drug-Metabolizing Enzymes Using HepaRG Cells.
Ogasawara A; Kato N; Torimoto N; Aohara F; Ohashi R; Yamada Y; Taniguchi H
Drug Metab Lett; 2018; 12(1):14-23. PubMed ID: 29357810
[TBL] [Abstract][Full Text] [Related]
10. Effects of mammalian CYP3A inducers on CYP3A-related enzyme activities in grass carp (Ctenopharyngodon idellus): Possible implications for the establishment of a fish CYP3A induction model.
Li D; Yang XL; Zhang SJ; Lin M; Yu WJ; Hu K
Comp Biochem Physiol C Toxicol Pharmacol; 2008 Jan; 147(1):17-29. PubMed ID: 17826359
[TBL] [Abstract][Full Text] [Related]
11. Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs.
Xu Y; Zhou Y; Hayashi M; Shou M; Skiles GL
Drug Metab Dispos; 2011 Jul; 39(7):1139-48. PubMed ID: 21441468
[TBL] [Abstract][Full Text] [Related]
12. Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay.
Kozawa M; Honma M; Suzuki H
Drug Metab Dispos; 2009 Jun; 37(6):1234-41. PubMed ID: 19282397
[TBL] [Abstract][Full Text] [Related]
13. Predictive utility of in vitro rifampin induction data generated in fresh and cryopreserved human hepatocytes, Fa2N-4, and HepaRG cells.
Templeton IE; Houston JB; Galetin A
Drug Metab Dispos; 2011 Oct; 39(10):1921-9. PubMed ID: 21771933
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions.
Sun Y; Chothe PP; Sager JE; Tsao H; Moore A; Laitinen L; Hariparsad N
Drug Metab Dispos; 2017 Jun; 45(6):692-705. PubMed ID: 28336578
[TBL] [Abstract][Full Text] [Related]
15. Activation of the aryl hydrocarbon receptor decreases rifampicin-induced CYP3A4 expression in primary human hepatocytes and HepaRG.
Rasmussen MK; Daujat-Chavanieu M; Gerbal-Chaloin S
Toxicol Lett; 2017 Aug; 277():1-8. PubMed ID: 28571685
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction.
Kim S; Dinchuk JE; Anthony MN; Orcutt T; Zoeckler ME; Sauer MB; Mosure KW; Vuppugalla R; Grace JE; Simmermacher J; Dulac HA; Pizzano J; Sinz M
Drug Metab Dispos; 2010 Jan; 38(1):16-24. PubMed ID: 19833845
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells.
McGinnity DF; Zhang G; Kenny JR; Hamilton GA; Otmani S; Stams KR; Haney S; Brassil P; Stresser DM; Riley RJ
Drug Metab Dispos; 2009 Jun; 37(6):1259-68. PubMed ID: 19307295
[TBL] [Abstract][Full Text] [Related]
18. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital.
Hariparsad N; Nallani SC; Sane RS; Buckley DJ; Buckley AR; Desai PB
J Clin Pharmacol; 2004 Nov; 44(11):1273-81. PubMed ID: 15496645
[TBL] [Abstract][Full Text] [Related]
19. New Screening Criteria Setting on Evaluation of Cytochrome P450 Induction Using HepaRG Cells with Multiplex Branched DNA Technologies in Early Drug Discovery.
Ogasawara A; Torimoto N; Tsuda N; Aohara F; Ohashi R; Yamada Y; Taniguchi H
Drug Metab Lett; 2016; 10(3):152-160. PubMed ID: 27550199
[TBL] [Abstract][Full Text] [Related]
20. Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes.
Graham RA; Tyler LO; Krol WL; Silver IS; Webster LO; Clark P; Chen L; Banks T; LeCluyse EL
J Biochem Mol Toxicol; 2006; 20(2):69-78. PubMed ID: 16615094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
